News

Filter

Current filters:

TysabriRituxan

1 to 9 of 33 results

Biogen Idec 2009 results beat forecasts, boosted by Tysabri sales growth

10-02-2010

US biotechnology firm Biogen Idec reported total revenues for full-year 2009 of $4.4 billion, an increase…

AvonexBiogen IdecBiotechnologyFinancialInterferon beta-1aNatalizumabPharmaceuticalRebifRituxanrituximabTysabri

Biogen's 1st-qtr profit jumps 54% to $244M

20-04-2009

US biotechnology firm Biogen Idec's first quarter 2009 earnings jumped 54% year-on-year to $243.9 million,…

Aventis PharmaAvonexBiogen IdecGenentechInterferon beta-1aNatalizumabRebifRituxanrituximabSanofi-AventisTysabri

Biogen Idec's full-year 2008 sales jump 33%

16-02-2009

US biotechnology firm Biogen Idec saw full-year 2008 GAAP diluted earnings of $2.65 per share, up 33%…

AvonexBiogen IdecInterferon beta-1aNatalizumabRebifRituxanrituximabTysabri

Biogen's 3rd-qtr EPS up 71% on drug sales

03-11-2008

US biotechnology firm Biogen Idec's third-quarter 2008 revenues soared 38% year-on-year to $1.09 billion…

AvonexBiogen IdecInterferon beta-1aNatalizumabRebifRituxanrituximabTysabri

Genentech/Biogen Idec's Rituxan linked to death of RA patient due to PML

22-09-2008

US biotechnology giant Genentech has warned doctors that its rheumatoid arthritis drug Rituxan (rituximab)…

Biogen IdecGenentechNatalizumabRituxanrituximabTysabri

1 to 9 of 33 results

Back to top